Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Fusion driven JMML: a novel CCDC88C-FLT3 fusion responsive to sorafenib identified by RNA sequencing.

Chao AK, Meyer JA, Lee AG, Hecht A, Tarver T, Van Ziffle J, Koegel AK, Golden C, Braun BS, Sweet-Cordero EA, Smith CC, Dvorak CC, Loh ML, Stieglitz E.

Leukemia. 2019 Sep 12. doi: 10.1038/s41375-019-0549-y. [Epub ahead of print] No abstract available.

PMID:
31511612
2.

Tissue-Specific Oncogenic Activity of KRASA146T.

Poulin EJ, Bera AK, Lu J, Lin YJ, Strasser SD, Paulo JA, Huang TQ, Morales C, Yan W, Cook J, Nowak JA, Brubaker DK, Joughin BA, Johnson CW, DeStefanis RA, Ghazi PC, Gondi S, Wales TE, Iacob RE, Bogdanova L, Gierut JJ, Li Y, Engen JR, Perez-Mancera PA, Braun BS, Gygi SP, Lauffenburger DA, Westover KD, Haigis KM.

Cancer Discov. 2019 Jun;9(6):738-755. doi: 10.1158/2159-8290.CD-18-1220. Epub 2019 Apr 5.

PMID:
30952657
3.

Bcl-2 Is a Therapeutic Target for Hypodiploid B-Lineage Acute Lymphoblastic Leukemia.

Diaz-Flores E, Comeaux EQ, Kim KL, Melnik E, Beckman K, Davis KL, Wu K, Akutagawa J, Bridges O, Marino R, Wohlfeil M, Braun BS, Mullighan CG, Loh ML.

Cancer Res. 2019 May 1;79(9):2339-2351. doi: 10.1158/0008-5472.CAN-18-0236. Epub 2019 Mar 12.

PMID:
30862722
4.

Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia.

Stieglitz E, Mazor T, Olshen AB, Geng H, Gelston LC, Akutagawa J, Lipka DB, Plass C, Flotho C, Chehab FF, Braun BS, Costello JF, Loh ML.

Nat Commun. 2017 Dec 19;8(1):2127. doi: 10.1038/s41467-017-02178-9.

5.

A Collaborative Model for Accelerating the Discovery and Translation of Cancer Therapies.

Maertens O, McCurrach ME, Braun BS, De Raedt T, Epstein I, Huang TQ, Lauchle JO, Lee H, Wu J, Cripe TP, Clapp DW, Ratner N, Shannon K, Cichowski K.

Cancer Res. 2017 Nov 1;77(21):5706-5711. doi: 10.1158/0008-5472.CAN-17-1789. Epub 2017 Oct 9. Review.

6.

Targeting the PI3K/Akt pathway in murine MDS/MPN driven by hyperactive Ras.

Akutagawa J, Huang TQ, Epstein I, Chang T, Quirindongo-Crespo M, Cottonham CL, Dail M, Slusher BS, Friedman LS, Sampath D, Braun BS.

Leukemia. 2016 Jun;30(6):1335-43. doi: 10.1038/leu.2016.14. Epub 2016 Feb 12.

7.

Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.

Chang T, Krisman K, Theobald EH, Xu J, Akutagawa J, Lauchle JO, Kogan S, Braun BS, Shannon K.

J Clin Invest. 2016 Jan;126(1):404. doi: 10.1172/JCI85325. Epub 2016 Jan 4. No abstract available.

8.

Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia.

Stieglitz E, Troup CB, Gelston LC, Haliburton J, Chow ED, Yu KB, Akutagawa J, Taylor-Weiner AN, Liu YL, Wang YD, Beckman K, Emanuel PD, Braun BS, Abate A, Gerbing RB, Alonzo TA, Loh ML.

Blood. 2015 Jan 15;125(3):516-24. doi: 10.1182/blood-2014-09-601690. Epub 2014 Nov 13.

9.

Traxtile: Interactive editing of cell tracks in time-lapse images.

Braun BS.

Biotechniques. 2015 Aug 1;59(2):82-6. doi: 10.2144/000114318. eCollection 2015 Aug.

10.

PLC-γ and PI3K link cytokines to ERK activation in hematopoietic cells with normal and oncogenic Kras.

Diaz-Flores E, Goldschmidt H, Depeille P, Ng V, Akutagawa J, Krisman K, Crone M, Burgess MR, Williams O, Houseman B, Shokat K, Sampath D, Bollag G, Roose JP, Braun BS, Shannon K.

Sci Signal. 2013 Dec 3;6(304):ra105. doi: 10.1126/scisignal.2004125.

11.

Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.

Chang T, Krisman K, Theobald EH, Xu J, Akutagawa J, Lauchle JO, Kogan S, Braun BS, Shannon K.

J Clin Invest. 2013 Jan;123(1):335-9. doi: 10.1172/JCI63193. Epub 2012 Dec 10. Erratum in: J Clin Invest. 2016 Jan;126(1):404.

12.

KIT's ship comes in.

Braun BS.

Blood. 2012 Sep 27;120(13):2541-2. No abstract available.

13.

Targeting oncogenic Ras signaling in hematologic malignancies.

Ward AF, Braun BS, Shannon KM.

Blood. 2012 Oct 25;120(17):3397-406. doi: 10.1182/blood-2012-05-378596. Epub 2012 Aug 16. Review.

14.

A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice.

Lyubynska N, Gorman MF, Lauchle JO, Hong WX, Akutagawa JK, Shannon K, Braun BS.

Sci Transl Med. 2011 Mar 30;3(76):76ra27. doi: 10.1126/scitranslmed.3001069.

15.

Essential role for Ptpn11 in survival of hematopoietic stem and progenitor cells.

Chan G, Cheung LS, Yang W, Milyavsky M, Sanders AD, Gu S, Hong WX, Liu AX, Wang X, Barbara M, Sharma T, Gavin J, Kutok JL, Iscove NN, Shannon KM, Dick JE, Neel BG, Braun BS.

Blood. 2011 Apr 21;117(16):4253-61. doi: 10.1182/blood-2010-11-319517. Epub 2011 Feb 25.

16.

Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus.

Li Q, Haigis KM, McDaniel A, Harding-Theobald E, Kogan SC, Akagi K, Wong JC, Braun BS, Wolff L, Jacks T, Shannon K.

Blood. 2011 Feb 10;117(6):2022-32. doi: 10.1182/blood-2010-04-280750. Epub 2010 Dec 16.

17.

Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia.

Niemeyer CM, Kang MW, Shin DH, Furlan I, Erlacher M, Bunin NJ, Bunda S, Finklestein JZ, Gorr TA, Mehta P, Schmid I, Kropshofer G, Corbacioglu S, Lang PJ, Klein C, Schlegel PG, Heinzmann A, Schneider M, Starý J, van den Heuvel-Eibrink MM, Hasle H, Locatelli F, Sakai D, Archambeault S, Chen L, Russell RC, Sybingco SS, Ohh M, Braun BS, Flotho C, Loh ML.

Nat Genet. 2010 Sep;42(9):794-800. doi: 10.1038/ng.641. Epub 2010 Aug 8.

18.

Mutant Ikzf1, KrasG12D, and Notch1 cooperate in T lineage leukemogenesis and modulate responses to targeted agents.

Dail M, Li Q, McDaniel A, Wong J, Akagi K, Huang B, Kang HC, Kogan SC, Shokat K, Wolff L, Braun BS, Shannon K.

Proc Natl Acad Sci U S A. 2010 Mar 16;107(11):5106-11. doi: 10.1073/pnas.1001064107. Epub 2010 Mar 1.

19.

The SPS affair: a complex tale of illicit proliferation.

Braun BS, Shannon K.

Cancer Cell. 2009 Aug 4;16(2):87-8. doi: 10.1016/j.ccr.2009.07.005.

20.

JunB protects against myeloid malignancies by limiting hematopoietic stem cell proliferation and differentiation without affecting self-renewal.

Santaguida M, Schepers K, King B, Sabnis AJ, Forsberg EC, Attema JL, Braun BS, Passegué E.

Cancer Cell. 2009 Apr 7;15(4):341-52. doi: 10.1016/j.ccr.2009.02.016.

21.

Oncogenic Kras initiates leukemia in hematopoietic stem cells.

Sabnis AJ, Cheung LS, Dail M, Kang HC, Santaguida M, Hermiston ML, Passegué E, Shannon K, Braun BS.

PLoS Biol. 2009 Mar 17;7(3):e59. doi: 10.1371/journal.pbio.1000059.

22.

Pediatric malignancies: update on sarcomas and leukemia development in children.

Braun BS, Lessnick SL.

Curr Opin Genet Dev. 2009 Feb;19(1):92-6. doi: 10.1016/j.gde.2008.12.005. Epub 2009 Jan 29. Review.

PMID:
19186049
23.

Targeting Ras in myeloid leukemias.

Braun BS, Shannon K.

Clin Cancer Res. 2008 Apr 15;14(8):2249-52. doi: 10.1158/1078-0432.CCR-07-1005. Review.

24.

K-RasG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem/progenitor cells.

Van Meter ME, Díaz-Flores E, Archard JA, Passegué E, Irish JM, Kotecha N, Nolan GP, Shannon K, Braun BS.

Blood. 2007 May 1;109(9):3945-52. Epub 2006 Dec 27.

25.

Somatic activation of a conditional KrasG12D allele causes ineffective erythropoiesis in vivo.

Braun BS, Archard JA, Van Ziffle JA, Tuveson DA, Jacks TE, Shannon K.

Blood. 2006 Sep 15;108(6):2041-4. Epub 2006 May 23.

26.

Congenital leukemia cutis with subsequent development of leukemia.

Zhang IH, Zane LT, Braun BS, Maize J Jr, Zoger S, Loh ML.

J Am Acad Dermatol. 2006 Feb;54(2 Suppl):S22-7.

PMID:
16427986
27.

Inherited predispositions and hyperactive Ras in myeloid leukemogenesis.

Lauchle JO, Braun BS, Loh ML, Shannon K.

Pediatr Blood Cancer. 2006 May 1;46(5):579-85. Review.

PMID:
16261595
28.

The sum is greater than the FGFR1 partner.

Braun BS, Shannon K.

Cancer Cell. 2004 Mar;5(3):203-4. Review.

29.

Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder.

Le DT, Kong N, Zhu Y, Lauchle JO, Aiyigari A, Braun BS, Wang E, Kogan SC, Le Beau MM, Parada L, Shannon KM.

Blood. 2004 Jun 1;103(11):4243-50. Epub 2004 Feb 24.

30.

Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder.

Braun BS, Tuveson DA, Kong N, Le DT, Kogan SC, Rozmus J, Le Beau MM, Jacks TE, Shannon KM.

Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):597-602. Epub 2003 Dec 29.

31.

EWS/FLI1-induced manic fringe renders NIH 3T3 cells tumorigenic.

May WA, Arvand A, Thompson AD, Braun BS, Wright M, Denny CT.

Nat Genet. 1997 Dec;17(4):495-7.

PMID:
9398859
32.

EAT-2 is a novel SH2 domain containing protein that is up regulated by Ewing's sarcoma EWS/FLI1 fusion gene.

Thompson AD, Braun BS, Arvand A, Stewart SD, May WA, Chen E, Korenberg J, Denny C.

Oncogene. 1996 Dec 19;13(12):2649-58.

PMID:
9000139
33.

Identification of target genes for the Ewing's sarcoma EWS/FLI fusion protein by representational difference analysis.

Braun BS, Frieden R, Lessnick SL, May WA, Denny CT.

Mol Cell Biol. 1995 Aug;15(8):4623-30.

34.

A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1.

Jeon IS, Davis JN, Braun BS, Sublett JE, Roussel MF, Denny CT, Shapiro DN.

Oncogene. 1995 Mar 16;10(6):1229-34.

PMID:
7700648
35.

Multiple domains mediate transformation by the Ewing's sarcoma EWS/FLI-1 fusion gene.

Lessnick SL, Braun BS, Denny CT, May WA.

Oncogene. 1995 Feb 2;10(3):423-31.

PMID:
7845667
36.

Influence of hydrocarbon tail structure on quinone binding and electron-transfer performance at the QA and QB sites of the photosynthetic reaction center protein.

Warncke K, Gunner MR, Braun BS, Gu L, Yu CA, Bruce JM, Dutton PL.

Biochemistry. 1994 Jun 28;33(25):7830-41.

PMID:
8011647
37.

The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1.

May WA, Lessnick SL, Braun BS, Klemsz M, Lewis BC, Lunsford LB, Hromas R, Denny CT.

Mol Cell Biol. 1993 Dec;13(12):7393-8.

38.

Prevention of experimental autoimmune arthritis with a peptide fragment of type II collagen.

Ku G, Kronenberg M, Peacock DJ, Tempst P, Banquerigo ML, Braun BS, Reeve JR Jr, Brahn E.

Eur J Immunol. 1993 Mar;23(3):591-9.

PMID:
7680609
39.

Creation of a yeast artificial chromosome fragmentation vector based on lysine-2.

Lewis BC, Shah NP, Braun BS, Denny CT.

Genet Anal Tech Appl. 1992 Jun;9(3):86-90.

PMID:
1476795
40.

Determination of partition coefficients of quinones by high-performance liquid chromatography.

Braun BS, Benbow U, Lloyd-Williams P, Bruce JM, Dutton PL.

Methods Enzymol. 1986;125:119-29. No abstract available.

PMID:
3713532

Supplemental Content

Loading ...
Support Center